Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 18 2021 - 8:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
BLOCK LISTING SIX MONTHLY RETURN
Date: 18 May
2021
|
Name of applicant:
|
GlaxoSmithKline plc
|
|
Name of scheme:
|
GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan
|
|
Period of return:
|
From:
|
1 November 2020
|
To:
|
30 April 2021
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
0
|
|
Plus: The amount by
which the block scheme(s) has been increased since the date of the
last return (if any increase has been applied
for):
|
300,000
|
|
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
264,481
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
35,519
|
|
Name of applicant:
|
GlaxoSmithKline plc
|
|
Name of scheme:
|
GlaxoSmithKline plc Share Save Plan 2012
|
|
Period of return:
|
From:
|
1 November 2020
|
To:
|
30 April 2021
|
|
Balance of unallotted securities under scheme(s) from previous
return:
|
1,277,629
|
|
Plus: The amount by
which the block scheme(s) has been increased since the date of the
last return (if any increase has been applied
for):
|
360,000
|
|
Less: Number
of securities issued/allotted under scheme(s) during
period (see LR3.5.7G):
|
1,255,163
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
382,466
|
The following GlaxoSmithKline plc Employee Share Schemes have
expired and therefore will no longer be included in GlaxoSmithKline
plc's Block Listing Six Monthly Returns:
●
GlaxoSmithKline plc 2009 Deferred
Annual Bonus Plan
●
GlaxoSmithKline 2009 Share Option Plan
- Ordinary Shares
●
GlaxoSmithKline 2009 Share Option Plan
- ADS
|
Name of contact:
|
Victoria Whyte
|
|
Telephone number of contact:
|
020 8047 5000
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
18, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
